7 Biotechnology Stocks to Buy Now

STML, PCYC, ACOR, NWBO, SGEN, AMGN, BMRN improve in weekly rankings

   
7 Biotechnology Stocks to Buy Now

This week, seven biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

Stemline Therapeutics, Inc. (STML) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. For more information, get Portfolio Grader’s complete analysis of STML stock.

Pharmacyclics, Inc. (PCYC) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. For more information, get Portfolio Grader’s complete analysis of PCYC stock.

Acorda Therapeutics, Inc. (ACOR) boosts its rating from a C to a B this week. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. For more information, get Portfolio Grader’s complete analysis of ACOR stock.

Northwest Biotherapeutics, Inc. (NWBO) shows solid improvement this week. The company’s rating rises from a C to a B. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. For more information, get Portfolio Grader’s complete analysis of NWBO stock.

The rating of Seattle Genetics, Inc. (SGEN) moves up this week, rising from a C to a B. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. For more information, get Portfolio Grader’s complete analysis of SGEN stock.

Amgen (AMGN) gets a higher grade this week, advancing from a B last week to an A. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. The stock’s dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.

BioMarin Pharmaceutical (BMRN) is seeing ratings go up from a C last week to a B this week. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. For more information, get Portfolio Grader’s complete analysis of BMRN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2014/04/7-biotechnology-stocks-to-buy-now-stml-pcyc-acor-4/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.